APA (7th ed.) Citation

TO, G., A, R., US, B., C, P., M, L., TW, K., . . . SE, A. (2024). Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Annals of surgical oncology, 31(6), 4073. https://doi.org/10.1245/s10434-024-15011-7

Chicago Style (17th ed.) Citation

TO, Goetze, et al. "Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial." Annals of Surgical Oncology 31, no. 6 (2024): 4073. https://doi.org/10.1245/s10434-024-15011-7.

MLA (9th ed.) Citation

TO, Goetze, et al. "Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial." Annals of Surgical Oncology, vol. 31, no. 6, 2024, p. 4073, https://doi.org/10.1245/s10434-024-15011-7.